The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Astellas Pharma Inc. (ALPMY) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Astellas Pharma Inc. is one of 891 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Astellas Pharma Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ALPMY's full-year earnings has moved 14.7% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, ALPMY has moved about 23.8% on a year-to-date basis. At the same time, Medical stocks have lost an average of 5.1%. This shows that Astellas Pharma Inc. is outperforming its peers so far this year.
Another stock in the Medical sector, Adlai Nortye Ltd. Sponsored ADR (ANL), has outperformed the sector so far this year. The stock's year-to-date return is 745.1%.
For Adlai Nortye Ltd. Sponsored ADR, the consensus EPS estimate for the current year has increased 43.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Astellas Pharma Inc. is a member of the Medical - Drugs industry, which includes 133 individual companies and currently sits at #88 in the Zacks Industry Rank. On average, this group has gained an average of 1.5% so far this year, meaning that ALPMY is performing better in terms of year-to-date returns.
Adlai Nortye Ltd. Sponsored ADR, however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 436-stock industry is ranked #148. The industry has moved +2.1% so far this year.
Investors interested in the Medical sector may want to keep a close eye on Astellas Pharma Inc. and Adlai Nortye Ltd. Sponsored ADR as they attempt to continue their solid performance.
Zacks Names #1 Semiconductor Stock
This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.
See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Astellas Pharma Inc. (ALPMY): Free Stock Analysis Report
Adlai Nortye Ltd. Sponsored ADR (ANL): Free Stock Analysis Report